链霉素聚氰基丙烯酸正丁酯纳米粒小鼠体内抗结核菌活性的研究

Study on Antituberculosis Activity of Streptomycin Nanoparticles in Vivo

目的观察链霉素纳米粒的小鼠体内抗结核作用。方法以被结核分枝杆菌感染的小鼠为实验动物,以小鼠的体重变化、死亡率、心、肝、脾、肺等重要脏器的重量指数变化及病理改变为评判指标,对链霉素纳米粒的体内抗结核作用进行了观察,并与非纳米化的普通链霉素进行了对比。结果链霉素纳米粒在降低结核感染模型动物死亡率及减轻肺脏病变程度的作用方面均较普通链霉素有较大的增强。结论链霉素纳米化后抗结核作用增强。

Aim To explore the antituberculosis activity of streptomycin nanoparticles in vivo. Methods Mice tuberculosis models were used to study streptomycin nanoparticles＇s antituberculosis activity in vivo that was compared with streptomycin. The curative effect were evaluated by mice＇s body weight changes and mortality, weight and histopathology changes in the lung, liver and spleen tissues. Results The mortality and histopathology changes in lungs of the streptomycin nanoparticles group were lower compared with the non-nanoparticle drug. Conclusion The streptomycin＇s in vivo antimicrobial activity to mycobacterium tuberculosis was enhanced after being nanoparticlizied.